Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
Health on MSN13d
How Much Longer Do We Have to Wait for a Norovirus Vaccine?Despite millions of cases of norovirus in the U.S. each year—and a current surge in outbreaks—there is still no vaccine for ...
The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...
Based on this evidence, First Check determines that this viral video deceptively combines footage to falsely imply COVID ...
Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune ...
The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...
Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...
Evaxion Biotech A/S (EVAX), a clinical-stage TechBio company specializing in AI-driven vaccines, has announced the completion of ...
Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...
Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy ATLANTA, GA - (NEWMEDIAWIRE) - GeoVax Labs, ...
Trial remains on track for completion and data readout in the second half of 2025COPENHAGEN, Denmark, January 15, 2025 - Evaxion Biotech A/S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback